专利检索 cpc:"Y02A50/483" 第 1 页

1.

发明申请
DERIVATIVES OF KORORMICIN USEFUL AS ANTIBIOTICS 审中-公开

公开(公告)号：US20190083450A1

公开(公告)日：2019-03-21

申请号：US16192117

申请日：2018-11-15

申请人： Pavel Dibrov , Elena Dibrov , Grant Pierce

发明人： Pavel Dibrov , Elena Dibrov , Grant Pierce

IPC分类号： A61K31/341 , A61K31/16 , C07F9/655 , A61K31/365 , C07D307/66 , C07D309/30

CPC分类号： A61K31/341 , A61K31/16 , A61K31/365 , A61K2300/00 , A61P31/04 , C07D307/66 , C07D309/30 , C07F9/655 , C07F9/65515 , Y02A50/406 , Y02A50/478 , Y02A50/483

摘要： An antibiotic compound of formula (III): or a salt or stereoisomer thereof; wherein R1-R3 and R5-R10 are independently selected from the group consisting of H, alkyl group, substituted alkyl group, halogen, OH, NH2 and SH; R4 is H, alkyl group or substituted alkyl group; X1-X2 are independently selected from the group consisting of ═O, ═S, NH, H, alkyl, halogen, OH, SH and NH2; W is a saturated acyclic hydrocarbon chain of 1 to 15 carbon atoms; and Z is a neutral or positively charged organic group. The compounds are useful in treating bacterial diseases.

2.

发明申请
Antibacterial Pharmaceutical Combination and Method for Treating Gram-Negative Bacteria Infections 审中-公开

公开(公告)号：US20180353489A1

公开(公告)日：2018-12-13

申请号：US16108146

申请日：2018-08-22

申请人： TENNOR THERAPEUTICS (SUZHOU) LIMITED

发明人： Zhenkun Ma , Gregory Robertson , Xiaomei Wang

IPC分类号： A61K31/4375 , A61P31/04 , A61K38/12

CPC分类号： A61K31/4375 , A61K31/4545 , A61K38/12 , A61P31/04 , Y02A50/473 , Y02A50/475 , Y02A50/483

摘要： Provide herein is an antibacterial pharmaceutical combination for treating Gram negative bacterial infections, including a compound TNP-2092 and a cell membrane permeabilizer. Also provided herein is a method for treating Gram-negative bacteria infections in a subject, which includes administrating to the subject the antibacterial pharmaceutical combination.

3.

发明申请
CHITOSAN-DERIVATIVE COMPOUNDS AND METHODS OF CONTROLLING MICROBIAL POPULATIONS 审中-公开

公开(公告)号：US20180127518A1

公开(公告)日：2018-05-10

申请号：US15648006

申请日：2017-07-12

申请人： SYNEDGEN, INC.

发明人： Shenda M. Baker , William P. Wiesmann

IPC分类号： C08B37/08 , A61K8/73 , A61Q17/00 , A61Q11/00 , A61K31/722 , A61L2/232 , A61L2/235 , C08L5/08

CPC分类号： C08B37/003 , A61K8/736 , A61K31/722 , A61L2/232 , A61L2/235 , A61L2202/23 , A61L2202/24 , A61Q11/00 , A61Q17/005 , C08L5/08 , Y02A50/473 , Y02A50/475 , Y02A50/481 , Y02A50/483

摘要： The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

4.

发明申请
Composition for preventing or treating of colitis disease comprising Lactobacillus sakei K040706 as an active ingredient 审中-公开

公开(公告)号：US20180064766A1

公开(公告)日：2018-03-08

申请号：US15643712

申请日：2017-07-07

申请人： KOREA FOOD RESEARCH INSTITUTE

发明人： Young Kyoung RHEE , Hee-Do HONG , Chang-Won CHO , Mi JANG , Tae-Gyu LIM , Young-Chul LEE , KyungTack KIM , Eun-Young HWANG , Kyung-Tae LEE , Ji-Sun SHIN , Seunghwan SEO , Young-ran SONG

IPC分类号： A61K35/747

CPC分类号： A61K35/747 , Y02A50/475 , Y02A50/483

摘要： The present invention relates to a composition for preventing or treating of colitis comprising Lactobacillus sakei K040706 as an active ingredient. More particularly, the present invention relates to a pharmaceutical composition or a food composition for preventing or treating colitis comprising Lactobacillus sakei K040706 (Accession No: KCCM11472P) as an active ingredient.Since Lactobacillus sakei K040706 of the present invention is capable of enhancing immune function such as increasing intestinal NO production ability and reducing the damage of intestinal tissue, Lactobacillus sakei K040706 may be useful for improving and treating colitis.

5.

发明授权
Compositions and methods comprising serratia peptidase for inhibition of bacterial vaginosis, bacterial vaginitis or fungal vaginitis 有权

公开(公告)号：US09737591B2

公开(公告)日：2017-08-22

申请号：US13072544

申请日：2011-03-25

申请人： Stephen Francis Olmstead

发明人： Stephen Francis Olmstead

IPC分类号： A61K38/54 , A61K38/46 , A61K38/47 , A61K9/00 , A61K38/40 , A61K38/48 , A61K36/82 , A61K31/352

CPC分类号： A61K38/47 , A61K9/0034 , A61K9/0043 , A61K9/0046 , A61K31/352 , A61K36/82 , A61K38/40 , A61K38/482 , A61K38/4873 , A61K38/4886 , Y02A50/406 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/481 , Y02A50/483 , A61K2300/00

摘要： Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.

6.

发明授权
Linear peptide antibiotics 有权

公开(公告)号：US09708368B2

公开(公告)日：2017-07-18

申请号：US14631762

申请日：2015-02-25

申请人： RQX Pharmaceuticals, Inc.

发明人： Robert I. Higuchi , Tucker Curran Roberts , Peter Andrew Smith , David Campbell , Prasuna Paraselli

IPC分类号： A61K38/06 , A61K38/07 , A61K38/08 , C07K5/08 , C07K5/10 , C07K7/06 , C07K5/11 , A61K45/06 , C07K5/113 , C07K5/103 , C07K5/117

CPC分类号： C07K7/06 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , C07K5/08 , C07K5/1013 , C07K5/1019 , C07K5/1021 , C07K5/1024 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483

摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

7.

发明授权
Use of aerosolized levofloxacin for treating cystic fibrosis 有权

公开(公告)号：US09700564B2

公开(公告)日：2017-07-11

申请号：US13412423

申请日：2012-03-05

申请人： Jeffery S. Loutit , Elizabeth E. Morgan , Michael N. Dudley , David C. Griffith , Olga Lomovskaya

发明人： Jeffery S. Loutit , Elizabeth E. Morgan , Michael N. Dudley , David C. Griffith , Olga Lomovskaya

IPC分类号： A61K31/5383 , A61K9/00 , A61K9/08 , A61K33/06 , A61K33/14 , A61K45/06

CPC分类号： A61K31/5383 , A61K9/0078 , A61K9/08 , A61K33/06 , A61K33/14 , A61K45/06 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483 , A61K2300/00

摘要： Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.

8.

发明授权
Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof 有权

公开(公告)号：US09687497B1

公开(公告)日：2017-06-27

申请号：US15309425

申请日：2015-04-29

申请人： Rempex Pharmaceuticals, Inc.

发明人： Joanna A. Bis , Pingyun Chen , Senthil Kumar Kusalakumari Sukumar

IPC分类号： A61K31/69 , C07F5/02 , A61K31/397 , A61K31/545

CPC分类号： A61K31/69 , A61K31/397 , A61K31/545 , A61K2121/00 , A61K2300/00 , C07F5/025 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483

摘要： Disclosed herein is the crystalline form of the potassium salt of 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid. The crystalline form maybe formulated for treating subjects with bacterial infection. Accordingly, some embodiments relate to compositions and methods of administering the potassium salt of 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid.

9.

发明授权
Boronic acid derivatives and therapeutic uses thereof 有权

公开(公告)号：US09642869B2

公开(公告)日：2017-05-09

申请号：US14146671

申请日：2014-01-02

申请人： Rempex Pharmaceuticals, Inc.

发明人： Raja K. Reddy , Tomasz Glinka , Maxim Totrov , Scott Hecker

IPC分类号： A61K31/69 , C07F5/04 , A61K45/06 , C07F5/02 , A61K31/407 , A61K31/4196 , A61K31/427 , A61K31/546

CPC分类号： A61K31/69 , A61K31/407 , A61K31/4196 , A61K31/427 , A61K31/546 , A61K45/06 , C07F5/025 , Y02A50/401 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483 , A61K2300/00

摘要： Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.